№ files_lp_4_process_3_139358
File format: docx
Character count: 1993
File size: 50 KB
Note:
Year
Topic:
Asthma Management
Document Type:
Health Advice
Target Audience:
Individuals with asthma
Context:
A health advisory document providing guidance on the proper use of reliever and preventer inhalers for asthma patients.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2020
Region:
Australia
Subject:
Asthma treatment; inhaled corticosteroids; combination therapy
Document type:
Regulatory submission summary
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Company:
Chiesi Australia Pty Ltd
Drug:
Fostair® (Beclometasone dipropionate 100 µg + Formoterol fumarate 6 µg)
Population:
Adults with asthma requiring ICS/LABA therapy
Comparator:
Budesonide/Formoterol (BUD/FOR 200/6) and other ICS/LABA formulations
Approval status:
TGA approved 12 February 2020
Therapy type:
Maintenance and reliever therapy (MART)
Clinical claim:
Non-inferior efficacy and safety compared to BUD/FOR 200/6 MART
Endpoints:
Time to first severe exacerbation, exacerbation rate, FEV1, ACQ score, reliever use
Submission type:
Category 2, Authority Required (Streamlined) listing
Context:
Regulatory source detailing clinical efficacy, safety, and PBS listing considerations for BEC/FOR 100/6 as a combined maintenance and reliever asthma therapy.
Year:
2025
Region / City:
Irvine, California
Topic:
Human Research Protection, IRB, FDA Compliance, HIPAA
Document Type:
Letter
Institution:
University of California, Irvine
Author:
UC Irvine Investigators
Target Audience:
Study sponsors, UC Irvine researchers
Effective Period:
Ongoing
Approval Date:
January 31, 2003
Amendment Date:
September 15, 2025
Year:
Not provided
Region / City:
Not provided
Theme:
Research methodology
Document type:
Academic paper
Organization:
AGH University of Science and Technology Press
Author:
Not specified
Target audience:
Researchers, academics, students
Period of validity:
Not specified
Approval date:
Not provided
Date of amendments:
Not provided
Year:
1940s
Region / City:
New Orleans
Topic:
Theatre, Southern Gothic, Symbolism, Social Change, American Dream
Document type:
Analytical Essay
Institution:
N/A
Author:
N/A
Target Audience:
Theatre students, Scholars of American Literature
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Note:
Contextual description
Year:
2006
Region / City:
Global
Theme:
Mental Health
Document Type:
Screening Tool
Organization / Institution:
Pfizer Inc.
Authors:
Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke
Target Audience:
Healthcare Professionals
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2026
Region / City:
Sweden / Western Europe
Topic:
Church growth and decline
Document Type:
Workshop summary / Research overview
Institution:
The Clapham Institute
Author:
Per Ewert
Target Audience:
Church leaders, theologians, religious researchers
Research Focus:
Comparative analysis of liberal and evangelical Protestant churches
Key Factors Discussed:
Secularization, institutionalization, evangelism, theological orientation
Methodology:
Observational and literature-based analysis of denominational trends
Period Covered:
Post-World War II to present
References:
Dean Kelley (1972), Roozen & Hadaway (1993), Stark & Finke (2005), Haskell, Flatt, and Burgoyne (2016)
Year:
2023
Region / City:
Bocking
Subject:
Education
Document Type:
Curriculum Policy
Organization:
Bocking School
Author:
Not specified
Target Audience:
Educators, Parents, Students
Duration:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
Not specified
Region / City:
Not specified
Topic:
Literature, Reading Response Journals
Document Type:
Educational Assignment
Institution:
Not specified
Author:
Geoffrey Trease
Target Audience:
Students
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Contextual Description
Year:
2025
Note:
Region / City
Topic:
Asthma Treatment
Document Type:
Quick Reference Guide
Organization / Institution:
LSCMMG
Target Audience:
Medical professionals, Patients over 12 years of age
Title of research:
Automating patient inhaler technique when using pressurised Metered Dose Inhalers: testing the functionality and impact of the aflo™ digital respiratory management platform in a randomised controlled trial in a primary care setting
Type of document:
Participant information sheet
Study design:
Randomised controlled trial
Setting:
Primary care
Target population:
Children aged 5 years or over with a diagnosis of asthma
Inclusion criteria:
Diagnosis of asthma; confirmed suitable by GP; access to smartphone and WIFI/4G; currently prescribed a spacer; adherence or symptom control issues
Intervention:
aflo™ digital respiratory management platform and inhaler device
Control:
Standard care
Study duration:
24 weeks
Appointments:
Three visits (baseline, 12 weeks, 24 weeks)
Procedures:
Questionnaires; inhaler technique demonstration; blood pressure measurement; lung function test; spirometry data access; blood sample collection
Sample collection:
Up to 8 ml blood at first appointment
Funding body:
Respiratory Analytics Ltd
Ethics approval:
West Midlands - Edgbaston Research Ethics Committee; MHRA
Compensation:
Travel reimbursement and £20 voucher
Data handling:
Anonymised data analysis; GP access to results
Note:
Year
Topic:
Asthma, Education, Health Management
Document Type:
Assessment Tool
Target Audience:
School personnel, parents, healthcare providers
Year:
2023
Region / City:
Cambridge, England
Subject:
Respiratory medicine, dry powder inhalers, design optimization
Document Type:
Research article
Organization / Institution:
Cambridge Healthcare Innovations, BnL Pharma Solutions, Owlstone Medical
Author:
Heather Jameson, David Harris, Jacob Harker, Karina Joyce, Helen Samuel, Max Allsworth
Target Audience:
Researchers, engineers, professionals in respiratory medicine and inhaler technology
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Note:
Year
Subject:
Asthma, COPD, Health
Document Type:
Instructional Guide
Organization / Institution:
Somerset CCG
Target Audience:
Patients with asthma or COPD
Context:
Instructional guide for patients on how to properly use the Accuhaler inhaler, including troubleshooting and common mistakes.
Document type:
Patient information leaflet
Medical device:
Spiromax inhaler
Related conditions:
Asthma; Chronic obstructive pulmonary disease (COPD)
Examples of products:
DuoResp Spiromax; Aerivio Spiromax
Purpose:
Guidance on correct inhaler technique and maintenance
Reassessment interval:
3 months; 6 months; 12 months
Intended audience:
Patients prescribed Spiromax inhalers
Issuing context:
Healthcare professional instruction
Associated resource:
Online video demonstrations
Year:
2026
Region / City:
Nottingham, UK
Subject:
Dry powder inhaler testing, aerodynamic particle size distribution
Document Type:
Research article
Institution:
Copley Scientific Ltd
Authors:
Ben Bradley, Mark Copley
Target Audience:
Scientists and laboratory technicians in pharmaceutical R&D and quality control
Tested Devices:
Symbicort® Turbohaler®
Experimental Methods:
Andersen Cascade Impactor (ACI), Next Generation Impactor (NGI), Fast Screening Andersen (FSA), Fast Screening Impactor (FSI)
Key Variables:
Flow rate rise-time, flow resistance, apparatus volume
Study Purpose:
To match flow rate rise-time profiles of abbreviated and full resolution impactors using a variable volume and flow resistance compensator
Year:
2026
Region / City:
Nottingham and Nottinghamshire, UK
Subject:
Prescription medication update
Document Type:
Patient letter
Organization / Institution:
NHS Nottingham and Nottinghamshire Integrated Care Board
Author:
Dr X
Target Audience:
Patients prescribed Fostair®
Medication:
Fostair® (beclometasone/formoterol) and Proxor® (beclometasone/formoterol)
Purpose:
Inform patients of inhaler switch and guidance on use
Date Issued:
2026-03-11
Year:
Not specified
Region / city:
Not specified
Subject:
Inhaler usage, asthma, COPD
Document type:
Instructional guide
Organization:
Not specified
Author:
Not specified
Target audience:
Patients with asthma and COPD
Effective period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2026
Region / City:
International
Topic:
Respiratory health, asthma, COPD
Document type:
Patient information leaflet
Organization / Institution:
Pharmaceutical company / Healthcare provider
Author:
Not specified
Target audience:
Patients prescribed Ellipta inhalers
Medication examples:
Relvar Ellipta, Anoro Ellipta, Incruse Ellipta
Common issues addressed:
Incorrect inhaler technique, dose management
Reference materials:
Video demonstration link provided
Review period:
At least annually
Year:
2020
Region:
Australia
Subject:
Asthma treatment; inhaled corticosteroids; combination therapy
Document type:
Regulatory submission summary
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Company:
Chiesi Australia Pty Ltd
Drug:
Fostair® (Beclometasone dipropionate 100 µg + Formoterol fumarate 6 µg)
Population:
Adults with asthma requiring ICS/LABA therapy
Comparator:
Budesonide/Formoterol (BUD/FOR 200/6) and other ICS/LABA formulations
Approval status:
TGA approved 12 February 2020
Therapy type:
Maintenance and reliever therapy (MART)
Clinical claim:
Non-inferior efficacy and safety compared to BUD/FOR 200/6 MART
Endpoints:
Time to first severe exacerbation, exacerbation rate, FEV1, ACQ score, reliever use
Submission type:
Category 2, Authority Required (Streamlined) listing
Context:
Regulatory source detailing clinical efficacy, safety, and PBS listing considerations for BEC/FOR 100/6 as a combined maintenance and reliever asthma therapy.